Two independent reports advance glioblastoma research from complementary angles: a 3D‑printed scaffold model that better replicates tumor microarchitecture for drug screening, and a separate study identifying COX‑2 as a mediator of chemoresistance amenable to therapeutic targeting. The scaffold platform, published in Annals of Biomedical Engineering by Sambamoorthy et al., delivers a more physiologic matrix for evaluating drug responses and heterogeneity. In parallel, a Medical Oncology study shows COX‑2 inhibition can re‑sensitize chemoresistant glioblastoma cells in preclinical models. Combined, these findings provide improved preclinical tools and a candidate target for translational efforts. Companies developing glioma therapies may prioritize screening on scaffold platforms and test COX‑2 combination regimens in early trials.